TABLE 3.
Proportion of Participants With hSBA Titers ≥1:8 at Day 0 and at Day 30 (Per Protocol Analysis Set)
| Serogroups | Time Point | MenACYW-TT | MenACWY-CRM | ||
|---|---|---|---|---|---|
| (n = 458) | (n = 460) | ||||
| n/M | % (95% CI) | n/M | % (95% CI) | ||
| A | Day 0 | 225/457 | 49.2 (44.6-53.9) | 224/460 | 48.7 (44.0-53.4) |
| Day 30 | 394/456 | 86.4 (82.9-89.4) | 363/458 | 79.3 (75.3-82.9) | |
| C | Day 0 | 56/458 | 12.2 (9.4-15.6) | 59/459 | 12.9 (9.9-16.3) |
| Day 30 | 448/458 | 97.8 (96.0-98.9) | 308/459 | 67.1 (62.6-71.4) | |
| W | Day 0 | 90/458 | 19.7 (16.1-23.6) | 93/460 | 20.2 (16.6-24.2) |
| Day 30 | 434/458 | 94.8 (92.3-96.9) | 396/459 | 86.3 (82.8-89.3) | |
| Y | Day 0 | 54/458 | 11.8 (9.0-15.1) | 57/460 | 12.4 (9.5-15.8) |
| Day 30 | 451/458 | 98.5 (96.9-99.4) | 417/459 | 90.8 (87.8-93.3) | |
CI, confidence interval; M, number of participants with a valid serology result for the particular serogroup and time point; n, number of participants experiencing the endpoint.
Titers ≥1:8 were considered seroprotective.